Conference Coverage

Laparoscopic surgery survival outcomes on par with open approach in colorectal liver metastases


 

REPORTING FROM ASCO 2019

– For colorectal cancer patients with liver metastases, laparoscopic surgery has short-term advantages over open surgery, including fewer complications and better quality of life as compared to open surgery. Now, there are data to show that long-term outcomes with the laparoscopic approach aren’t any worse with the laparoscopic approach.

In a video interview at the annual meeting of the American Society of Clinical Oncology, Åsmund Avdem Fretland, MD, discusses results of the 280-patient randomized OSLO-COMET study, including 5-year survival of 56% for the laparoscopic approach, and similarly, 57% for the open procedure.

Based on lower morbidity, and now similar life expectancy, more centers should be doing laparoscopic procedures for liver metastases, said Dr. Fretland, a surgeon in the department of HPB surgery at Oslo University Hospital.

For now, however, open surgery appears to be the dominant approach. According to a recent survey, just 22% of U.S. patients with colorectal liver metastases have laparoscopic surgery.

More data could help. Dr. Fretland said in the interview that more randomized trials are underway aimed at evaluating the long-term outcomes of laparoscopic versus open procedures.

Dr. Fretland reported honoraria from Olympus Medical Systems.

Recommended Reading

ASCO issues guideline for early detection, management of colorectal cancer
AVAHO
Endoscopic full-thickness resection shows promise in CRC
AVAHO
For patients with HBV, daily aspirin may reduce risk of liver cancer
AVAHO
Proinflammatory microbiome tied to colorectal adenoma
AVAHO
Study eyes biomarkers of regorafenib response in hepatocellular carcinoma
AVAHO
Novel chemo/PARP inhibitor strategy promising for advanced pancreatic cancer
AVAHO
Preclinical findings highlight value of Lynch syndrome for cancer vaccine development
AVAHO
Tenofovir disoproxil treated HBV with fewer future HCCs
AVAHO
AGA Clinical Practice Update: Direct-acting antivirals and hepatocellular carcinoma
AVAHO
Pembro as good as chemo for gastric cancers with less toxicity
AVAHO